HLS Therapeutics Inc (DE:74D)

HLS Therapeutics Inc (74D) Stock Price & Analysis


74D Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€4.58 - €11.03
Previous Close€4.58
Average Volume (3M)N/A
Market Cap
Enterprise Value€220.97M
Total Cash (Recent Filing)$21.16M
Total Debt (Recent Filing)$91.63M
Price to Earnings (P/E)N/A
May 11, 2023
0.15 (3.18%)
Share Statistics
Shares Outstanding32,377,223
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
Financial Highlights & Ratios
Price to Book (P/B)1.57
Price to Sales (P/S)3.04
Price to Cash Flow (P/CF)12.20
P/FCF Ratio-432.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit3.94
Enterprise Value/Ebitda10.29
Price Target Upside151.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4




What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was €4.58 and its highest was €11.03 in the past 12 months.
    What is HLS Therapeutics Inc’s market cap?
    Currently, no data Available
    When is HLS Therapeutics Inc’s upcoming earnings report date?
    HLS Therapeutics Inc’s upcoming earnings report date is May 11, 2023 which is in 51 days.
      How were HLS Therapeutics Inc’s earnings last quarter?
      HLS Therapeutics Inc released its earnings results on Mar 16, 2023. The company reported -€0.187 earnings per share for the quarter, missing the consensus estimate of -€0.079 by -€0.109.
        Is HLS Therapeutics Inc overvalued?
        According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does HLS Therapeutics Inc pay dividends?
          HLS Therapeutics Inc pays a Quarterly dividend of €0.03 which represents an annual dividend yield of 3.18%. See more information on HLS Therapeutics Inc dividends here
            What is HLS Therapeutics Inc’s EPS estimate?
            HLS Therapeutics Inc’s EPS estimate is -€0.11.
              How many shares outstanding does HLS Therapeutics Inc have?
              Currently, no data Available
              What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
              HLS Therapeutics Inc reported an EPS of -€0.187 in its last earnings report, missing expectations of -€0.079. Following the earnings report the stock price went down -19.649%.
                Which hedge fund is a major shareholder of HLS Therapeutics Inc?
                Currently, no hedge funds are holding shares in DE:74D


                HLS Therapeutics Inc Stock Smart Score

                The HLS Therapeutics Inc Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                HLS Therapeutics Inc

                HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                HLS Therapeutics Inc
                DRI Healthcare

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis